Cancer channel
The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
Bayer gains first Aliqopa approval in follicular lymphoma
September 15, 2017
ESMO 2017 round up: BMS and AZ bounce back
September 12, 2017
Colon cancer treatment can be shortened to spare patients toxicity
September 11, 2017
Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treatment
September 11, 2017
Tagrisso on target to be EGFR+ lung cancer standard
September 9, 2017
FDA puts hold on AZ and Celgene immunotherapy trials
September 8, 2017Regulator is exploring safety of immunotherapy combinations in blood cancer
Rubraca outshines rivals in ovarian cancer maintenance therapy
September 8, 2017Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
ESMO 2017 preview: AstraZeneca‘s comeback, IO shifts to earlier use
September 7, 2017A look ahead at some of the most eye-catching data and trends at ESMO 2017
Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer
September 6, 2017Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
Innovations in cancer drug research
September 4, 2017
